HEPACAM and Leukoencephalopathy: Based on the remitting edema phenotype of MLC2B patients, who carry one dominant mutation in the HEPACAM gene, we hypothesized that in vacuolating leukoencephalopathies such as MLC, or as it was demonstrated for similar pathologies such as Canavan’s or Pelizaeus-Merzbacher-like disease (Georgiou et al., 2017; Gessler et al., 2017), the therapeutic correction could be achieved even in advanced stages of the disease.